Proteomics International Laboratories Limited (PIQ.AX)
AUD 0.45
(0.0%)
AUD 0.45
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -6.32 Million AUD | -6.05% |
| 2023 | -5.96 Million AUD | -182.41% |
| 2022 | -2.11 Million AUD | 61.86% |
| 2021 | -5.53 Million AUD | -148.0% |
| 2020 | -2.23 Million AUD | -65.78% |
| 2019 | -1.34 Million AUD | 32.82% |
| 2018 | -2 Million AUD | -2099.26% |
| 2017 | 100.25 Thousand AUD | 171.42% |
| 2016 | -140.36 Thousand AUD | 91.02% |
| 2015 | -1.56 Million AUD | 68.36% |
| 2014 | -4.94 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q4 | -6.32 Million AUD | 0.0% |
| 2024 Q2 | -4.92 Million AUD | 0.0% |
| 2024 FY | -6.32 Million AUD | -6.05% |
| 2023 Q4 | -5.96 Million AUD | 1.06% |
| 2023 FY | -5.96 Million AUD | -182.41% |
| 2023 Q3 | -6.02 Million AUD | 11.65% |
| 2023 Q1 | -6.82 Million AUD | -223.09% |
| 2023 Q2 | -6.82 Million AUD | 0.0% |
| 2022 Q2 | -4.51 Million AUD | 0.0% |
| 2022 Q4 | -2.11 Million AUD | 0.0% |
| 2022 FY | -2.11 Million AUD | 61.86% |
| 2022 Q3 | -2.11 Million AUD | 53.23% |
| 2021 Q4 | -5.53 Million AUD | 1.23% |
| 2021 Q3 | -5.6 Million AUD | 24.67% |
| 2021 FY | -5.53 Million AUD | -148.0% |
| 2021 Q1 | -7.54 Million AUD | -237.85% |
| 2021 Q2 | -7.43 Million AUD | 1.34% |
| 2020 Q4 | -2.23 Million AUD | 5.62% |
| 2020 FY | -2.23 Million AUD | -65.78% |
| 2020 Q3 | -2.36 Million AUD | -3.16% |
| 2020 Q2 | -2.29 Million AUD | 0.0% |
| 2019 Q3 | -1.51 Million AUD | 46.79% |
| 2019 Q4 | -1.34 Million AUD | 10.91% |
| 2019 FY | -1.34 Million AUD | 32.82% |
| 2019 Q1 | -2.92 Million AUD | -45.95% |
| 2019 Q2 | -2.84 Million AUD | 2.9% |
| 2018 Q1 | -690.27 Thousand AUD | -788.52% |
| 2018 Q4 | -2 Million AUD | 13.49% |
| 2018 FY | -2 Million AUD | -2099.26% |
| 2018 Q2 | -83.16 Thousand AUD | 87.95% |
| 2018 Q3 | -2.31 Million AUD | -2685.73% |
| 2017 Q1 | -2.05 Million AUD | -1367.53% |
| 2017 FY | 100.25 Thousand AUD | 171.42% |
| 2017 Q4 | 100.25 Thousand AUD | 112.93% |
| 2017 Q2 | -1.61 Million AUD | 21.45% |
| 2017 Q3 | -775.14 Thousand AUD | 52.09% |
| 2016 Q3 | -582.25 Thousand AUD | 45.21% |
| 2016 Q1 | -1.5 Million AUD | 3.74% |
| 2016 FY | -140.36 Thousand AUD | 91.02% |
| 2016 Q4 | -140.36 Thousand AUD | 75.89% |
| 2016 Q2 | -1.06 Million AUD | 29.37% |
| 2015 Q1 | - AUD | 0.0% |
| 2015 Q4 | -1.56 Million AUD | 22.04% |
| 2015 FY | -1.56 Million AUD | 68.36% |
| 2015 Q3 | -2 Million AUD | 0.0% |
| 2014 FY | -4.94 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AdAlta Limited | -845.17 Thousand AUD | -648.231% |
| Acrux Limited | -1.45 Million AUD | -333.734% |
| Actinogen Medical Limited | -9.13 Million AUD | 30.748% |
| AnteoTech Limited | -5 Million AUD | -26.438% |
| Argenica Therapeutics Limited | -15.91 Million AUD | 60.259% |
| Arovella Therapeutics Limited | -12.71 Million AUD | 50.262% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | -543.906% |
| Alterity Therapeutics Limited | -12.47 Million AUD | 49.327% |
| Amplia Therapeutics Limited | -1.82 Million AUD | -246.78% |
| Avecho Biotechnology Limited | -5.32 Million AUD | -18.663% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | -791.238% |
| Biome Australia Limited | -1.56 Million AUD | -304.647% |
| Biotron Limited | -386.06 Thousand AUD | -1538.014% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 92.026% |
| BTC Health Limited | -2.02 Million AUD | -212.728% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | -107.136% |
| CSL Limited | 15.76 Billion AUD | 100.04% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 95.367% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 96.544% |
| Cynata Therapeutics Limited | -6.2 Million AUD | -1.909% |
| Dimerix Limited | -21.99 Million AUD | 71.244% |
| EZZ Life Science Holdings Limited | -18.89 Million AUD | 66.538% |
| Hexima Limited | -2.22 Million AUD | -184.063% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | -410.643% |
| Immuron Limited | -11.48 Million AUD | 44.933% |
| Immutep Limited | -122.18 Million AUD | 94.825% |
| Imugene Limited | -91.56 Million AUD | 93.093% |
| Invex Therapeutics Ltd | -6.02 Million AUD | -4.959% |
| Memphasys Limited | 4.13 Million AUD | 252.921% |
| Nanollose Limited | -96.22 Thousand AUD | -6471.94% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | 63.005% |
| Noxopharm Limited | -2.31 Million AUD | -172.588% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | -27.648% |
| Nyrada Inc. | -4.76 Million AUD | -32.593% |
| Orthocell Limited | -19.92 Million AUD | 68.261% |
| PharmAust Limited | -9.71 Million AUD | 34.9% |
| Patrys Limited | -2.24 Million AUD | -182.231% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | 64.031% |
| Prescient Therapeutics Limited | -10.16 Million AUD | 37.774% |
| PYC Therapeutics Limited | -65.76 Million AUD | 90.384% |
| Race Oncology Limited | -17.18 Million AUD | 63.21% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | 65.955% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | -86.207% |
| Starpharma Holdings Limited | -19.83 Million AUD | 68.113% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 94.022% |
| Tissue Repair Ltd | -16.44 Million AUD | 61.536% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 224.796% |